In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Recent breakthroughs in understanding the prostaglandin D2 (PGD2) receptor 1 (DP1) are paving the way for innovative ...

Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

The global ablation technology market was valued at US$ 6.82 billion in 2024 and is projected to reach US$ 16.74 billion by ...

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a ...

Golidocitinib combined with PD-1 antibodies achieved a 44.3% response rate in NSCLC patients post anti-PD-1 therapy progression. The combination therapy showed a complete response rate of 23.9% and a ...

PD-1 is a cell-surface receptor that resides on T and B cells, keeping immune cells from attacking other cells within the body. This prevents autoimmune diseases but also prevents the immune system ...

Since its discovery in the 1990s, “programmed cell death protein 1,” or PD-1, has been regarded as a leading target in cancer treatments. A “checkpoint” receptor that often resides on the surface of ...

With evidence from 85,373 participants across 11 trials, GLP-1 receptor agonists significantly reduced kidney failure risk and cardiovascular events, showing consistent benefits across diabetes ...

S-4321 was designed using the Company’s IMPACT platform to agonize the inhibitory PD-1 receptor on T cells in the similar manner as its natural ligand, and to selectively bind and agonize the ...

LaNova's key clinical stage pipeline programs and expected upcoming milestones LM-299 (Anti-PD-1/VEGF bispecific antibody) LM-299 is a bispecific antibody developed by LaNova that targets both PD-1 ...